Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
Summary
Antengene signed an exclusive global license agreement with K2 Therapeutics for ATG-106, a preclinical CDH6 x CD3 bispecific T cell engager for solid tumors. Antengene also gave K2 an option on an additional undisclosed bispecific TCE program. The deal brings Antengene about $20 million in upfront and near-term consideration and gives it the potential for up to $960.5 million in milestones plus royalties. K2 gains global development and commercialization rights outside Greater China, while Antengene extends its platform partnering strategy after a prior agreement with UCB.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected